

PEDIATRIC CANCER RESEARCH FOUNDATION (A NONPROFIT ORGANIZATION)

FINANCIAL STATEMENTS

June 30, 2025

With Comparative Totals for the Six-Month Period
Ended June 30, 2024

CONTENTS

Independent Auditors' Report	1-2
Statement of Financial Position.....	3
Statement of Activities and Changes in Net Assets.....	4
Statement of Functional Expenses	5
Statement of Cash Flows	6
Notes to the Financial Statements	7-19

INDEPENDENT AUDITORS' REPORT

To the Board of Directors of
Pediatric Cancer Research Foundation

Opinion

We have audited the accompanying financial statements of Pediatric Cancer Research Foundation (the Foundation), which comprise the statement of financial position as of June 30, 2025, and the related statements of activities and changes in net assets, functional expenses, and cash flows for the year then ended, and the related notes to the financial statements.

In our opinion, the financial statements referred to above present fairly, in all material respects, the financial position of the Foundation as of June 30, 2025, and the changes in its net assets and its cash flows for the year then ended in accordance with accounting principles generally accepted in the United States of America.

Basis for Opinion

We conducted our audit in accordance with auditing standards generally accepted in the United States of America. Our responsibilities under those standards are further described in the Auditors' Responsibilities for the Audit of the Financial Statements section of our report. We are required to be independent of the Foundation and to meet our other ethical responsibilities in accordance with the relevant ethical requirements relating to our audit. We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our audit opinion.

Responsibilities of Management for the Financial Statements

Management is responsible for the preparation and fair presentation of the financial statements in accordance with accounting principles generally accepted in the United States of America, and for the design, implementation, and maintenance of internal control relevant to the preparation and fair presentation of financial statements that are free from material misstatement, whether due to fraud or error.

In preparing the financial statements, management is required to evaluate whether there are conditions or events, considered in the aggregate, that raise substantial doubt about the Foundation's ability to continue as a going concern within one year after the date that the financial statements are available to be issued.

Auditors' Responsibilities for the Audit of the Financial Statements

Our objectives are to obtain reasonable assurance about whether the financial statements as a whole are free from material misstatement, whether due to fraud or error, and to issue an auditors' report that includes our opinion. Reasonable assurance is a high level of assurance but is not absolute assurance and, therefore, is not a guarantee that an audit conducted in accordance with generally accepted auditing standards will always detect a material misstatement when it exists. The risk of not detecting a material misstatement resulting from fraud is higher than for one resulting from error, as fraud may involve collusion, forgery, intentional omissions, misrepresentations, or the override of internal control. Misstatements are considered material if there is a substantial likelihood that, individually or in the aggregate, they would influence the judgment made by a reasonable user based on the financial statements.

In performing an audit in accordance with generally accepted auditing standards, we:

- Exercise professional judgment and maintain professional skepticism throughout the audit.
- Identify and assess the risks of material misstatement of the financial statements, whether due to fraud or error, and design and perform audit procedures responsive to those risks. Such procedures include examining, on a test basis, evidence regarding the amounts and disclosures in the financial statements.
- Obtain an understanding of internal control relevant to the audit in order to design audit procedures that are appropriate in the circumstances, but not for the purpose of expressing an opinion on the effectiveness of the Foundation's internal control. Accordingly, no such opinion is expressed.
- Evaluate the appropriateness of accounting policies used and the reasonableness of significant accounting estimates made by management, as well as evaluate the overall presentation of the financial statements.
- Conclude whether, in our judgment, there are conditions or events, considered in the aggregate, that raise substantial doubt about the Foundation's ability to continue as a going concern for a reasonable period of time.

We are required to communicate with those charged with governance regarding, among other matters, the planned scope and timing of the audit, significant audit findings, and certain internal control-related matters that we identified during the audit.

Report on Summarized Comparative Information

We have previously audited the financial statements of the Foundation as of and for the six-month period ended June 30, 2024, and we have expressed an unmodified opinion on those statements in our report dated January 27, 2025. The summarized comparative information presented herein as of and for the six-month period ended June 30, 2024, is consistent in all material respects with the audited financial statements from which it has been derived.

Winder, Inc.

Irvine, California
January 29, 2026

PEDIATRIC CANCER RESEARCH FOUNDATION
STATEMENT OF FINANCIAL POSITION
JUNE 30, 2025
(WITH COMPARATIVE TOTALS FOR JUNE 30, 2024)

ASSETS

	June 30,	
	2025	2024
ASSETS		
Cash and cash equivalents	\$ 1,407,608	\$ 663,371
Investments	356,929	1,574,083
Contributions receivable	49,774	69,831
Pledges receivable, net	1,175,137	-
Other assets	163,825	119,430
Operating lease right-of-use assets	279,896	252,278
Investment, at cost	250,000	250,000
TOTAL ASSETS	\$ 3,683,169	\$ 2,928,993

LIABILITIES AND NET ASSETS

LIABILITIES		
Accounts payable and accrued expenses	\$ 207,812	\$ 164,469
Grants payable	797,967	965,847
Deferred revenue	641,517	325,351
Operating lease liabilities	323,952	283,077
TOTAL LIABILITIES	1,971,248	1,738,744
CONTINGENCIES (Note 7)		
NET ASSETS		
Without donor restrictions	526,234	1,190,249
With donor restrictions	1,185,687	-
TOTAL NET ASSETS	1,711,921	1,190,249
TOTAL LIABILITIES AND NET ASSETS	\$ 3,683,169	\$ 2,928,993

The accompanying notes are an integral part of these financial statements.

PEDIATRIC CANCER RESEARCH FOUNDATION

**STATEMENT OF ACTIVITIES AND CHANGES IN NET ASSETS
FOR THE YEAR ENDED JUNE 30, 2025**

(WITH COMPARATIVE TOTALS FOR THE SIX-MONTH PERIOD ENDED JUNE 30, 2024)

	<u>Without Donor Restrictions</u>	<u>With Donor Restrictions</u>	<u>Total</u>	
			<u>2025</u>	<u>2024</u>
Revenue and support:				
General public support	\$ 727,680	\$ 1,070,207	\$ 1,797,887	\$ 969,645
Special events, net of direct costs of \$771,525 in 2025 and \$426,678 in 2024	2,100,454	261,930	2,362,384	376,095
In-kind contributions	17,374	-	17,374	-
Investment return, net	91,644	-	91,644	27,072
Net assets released from restrictions	<u>146,450</u>	<u>(146,450)</u>	<u>-</u>	<u>-</u>
Total revenue and support	<u>3,083,602</u>	<u>1,185,687</u>	<u>4,269,289</u>	<u>1,372,812</u>
Expenses:				
Program services:				
Pediatric cancer research	2,261,147	-	2,261,147	1,193,411
Support services:				
Management and general	246,897	-	246,897	80,416
Fundraising	<u>1,239,573</u>	<u>-</u>	<u>1,239,573</u>	<u>638,699</u>
Total expenses	<u>3,747,617</u>	<u>-</u>	<u>3,747,617</u>	<u>1,912,526</u>
Change in net assets	(664,015)	1,185,687	521,672	(539,714)
Net assets, beginning of year/period	<u>1,190,249</u>	<u>-</u>	<u>1,190,249</u>	<u>1,729,963</u>
Net assets, end of year/period	<u>\$ 526,234</u>	<u>\$ 1,185,687</u>	<u>\$ 1,711,921</u>	<u>\$ 1,190,249</u>

The accompanying notes are an integral part of these financial statements.

PEDIATRIC CANCER RESEARCH FOUNDATION

**STATEMENT OF FUNCTIONAL EXPENSES
FOR THE YEAR ENDED JUNE 30, 2025**

(WITH COMPARATIVE TOTALS FOR THE SIX-MONTH PERIOD ENDED JUNE 30, 2024)

	Program Services	Support Services			
	Pediatric Cancer Research	Management and General	Fundraising	2025 Total	2024 Total
Grants for pediatric cancer research	\$ 1,425,451	\$ -	\$ -	\$ 1,425,451	\$ 887,306
Other program services and support	270,467	-	-	270,467	42,758
Salaries and related costs	370,715	124,868	692,216	1,187,799	483,560
Postage, printing, and supplies	6,284	9,426	15,710	31,420	10,134
Rent and utilities	48,994	16,491	91,472	156,957	59,291
Professional services	82,232	24,369	260,666	367,267	256,469
Public relations and marketing	50,180	-	139,948	190,128	151,820
Credit card fees	-	1,153	10,643	11,796	5,437
Insurance	4,002	2,751	10,388	17,141	8,850
Donations, in-kind	-	17,374	-	17,374	-
Dues, subscriptions, and other	2,822	50,465	18,530	71,817	6,901
 Total expenses	\$ 2,261,147	\$ 246,897	\$ 1,239,573	\$ 3,747,617	\$ 1,912,526

The accompanying notes are an integral part of these financial statements.

PEDIATRIC CANCER RESEARCH FOUNDATION

**STATEMENT OF CASH FLOWS
FOR THE YEAR ENDED JUNE 30, 2025
(WITH COMPARATIVE TOTALS FOR THE SIX-MONTH PERIOD ENDED JUNE 30, 2024)**

	For the Year Ended June 30, 2025	For the Six-Month Period Ended June 30, 2024
	<u>2025</u>	<u>2024</u>
CASH FLOWS FROM OPERATING ACTIVITIES		
Change in net assets	\$ 521,672	\$ (539,714)
Adjustments to reconcile change in net assets to net cash from operating activities:		
Amortization of operating lease right-of-use assets	87,481	33,967
Realized and unrealized (gain) loss on investments	(27,091)	11,537
Changes in operating assets and liabilities:		
Contributions receivable	20,057	51,514
Pledges receivable	(1,175,137)	-
Other assets	(44,395)	1,408
Accounts payable and accrued expenses	43,343	(83,005)
Grants payable	(167,880)	119,425
Deferred revenue	316,166	161,170
Operating lease liabilities	(74,224)	(34,819)
Net Cash Used In Operating Activities	<u>(500,008)</u>	<u>(278,517)</u>
CASH FLOWS FROM INVESTING ACTIVITIES		
Purchase of investments	(80,755)	(1,085,911)
Proceeds from sale of investments	<u>1,325,000</u>	<u>500,000</u>
Net Cash Provided By (Used In) Investing Activities	<u>1,244,245</u>	<u>(585,911)</u>
NET CHANGE IN CASH AND CASH EQUIVALENTS	744,237	(864,428)
CASH AND CASH EQUIVALENTS, BEGINNING OF YEAR/PERIOD	<u>663,371</u>	<u>1,527,799</u>
CASH AND CASH EQUIVALENTS, END OF YEAR/PERIOD	<u>\$ 1,407,608</u>	<u>\$ 663,371</u>

The accompanying notes are an integral part of these financial statements.

PEDIATRIC CANCER RESEARCH FOUNDATION

NOTES TO THE FINANCIAL STATEMENTS

JUNE 30, 2025

NOTE 1 – Summary of Significant Accounting Policies

Organization and Business Activity of the Reporting Entity

Pediatric Cancer Research Foundation (the Foundation) is a nonprofit public benefit corporation incorporated on December 2, 1982 under the laws of the state of California. The Foundation is headquartered in Irvine, California. The Foundation is primarily engaged in fundraising activities and awarding grants to organizations for the purpose of funding pediatric cancer research.

Basis of Presentation

The Foundation prepares its financial statements in accordance with accounting principles generally accepted in the United States of America (U.S. GAAP), which involves the application of accrual accounting; consequently, revenue and gains are recognized when earned, and expenses and losses are recognized when incurred.

Financial Statement Presentation

The Foundation reports information regarding its financial position and activities according to two classes of net assets: net assets without donor restrictions and net assets with donor restrictions. Net assets, revenue, and gains and losses are classified based on the existence or absence of donor-imposed restrictions as follows:

Net Assets Without Donor Restrictions – Net assets that are not subject to donor-imposed restrictions.

Net Assets With Donor Restrictions – Net assets subject to donor-imposed restrictions that will be met either by actions of the Foundation or the passage of time. As restrictions are satisfied, net assets with donor restrictions are reclassified to net assets without donor restrictions and reported in the statement of activities and changes in net assets as net assets released from restrictions. When donor restrictions on contributions are satisfied in the same period as the receipt of the contribution, the Foundation reports both the revenue and the related expense in net assets without donor restrictions.

Net assets with donor restrictions also include net assets subject to donor-imposed restrictions that the corpus be invested in perpetuity and only the income be made available for program operations in accordance with donor restrictions. Such income generally includes interest, dividends, and realized and unrealized earnings from the corpus.

PEDIATRIC CANCER RESEARCH FOUNDATION

NOTES TO THE FINANCIAL STATEMENTS

JUNE 30, 2025

NOTE 1 – Summary of Significant Accounting Policies (Continued)

Use of Estimates

The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, and disclosures of contingent assets and liabilities at the date of the financial statements, and the reported amounts of revenue and expenses during the reporting period. Actual results could differ from those estimates.

Prior-Period Comparative Information

The financial statements include certain prior-period summarized comparative information in total, but not by net asset class. Such information does not include sufficient detail to constitute a presentation in conformity with U.S. GAAP. Accordingly, such information should be read in conjunction with the Foundation's financial statements for the six-month period ended June 30, 2024, from which the summarized information was derived.

Cash and Cash Equivalents

The Foundation considers cash on hand, money market accounts, and all highly liquid investments with original maturities of three months or less to be cash and cash equivalents.

Investments

Investments are reported in the accompanying statement of financial position at fair value. Investment return includes changes in fair value, dividends and interest, and any realized or unrealized gains or losses that occur during the fiscal year.

PEDIATRIC CANCER RESEARCH FOUNDATION

NOTES TO THE FINANCIAL STATEMENTS

JUNE 30, 2025

NOTE 1 – Summary of Significant Accounting Policies (Continued)

Contributions Receivable

Receivables are stated at unpaid balances, less an allowance for credit losses. The Foundation provides for losses on receivables using the current expected credit loss “CECL” methodology. The allowance is based on historical loss experience, current economic conditions, and other relevant factors in its credit loss estimation process and provides for probable uncollectable amounts through a charge to earnings and a credit to an allowance for credit losses based on its assessment. Balances which are still outstanding after management has used reasonable collection efforts are written off through a charge to the allowance for credit losses allowance and a credit to contributions receivable. Although the Foundation expects to collect amounts due, actual collections may differ. There was no allowance for credit losses for the year ended June 30, 2025. The Foundation recognized no credit losses and no bad debt expense for the year ended June 30, 2025. At June 30, 2025, management considers receivables to be fully collectible.

Pledges Receivable

Pledges receivable (unconditional promises to give) are recorded at net realizable value. Pledges expected to be collected over a period in excess of one year are recorded at the present value of their estimated future cash flows, discounted using estimated market return rates of 3 – 5%. Conditional promises to give are not included as support until the conditions are substantially met.

Other Assets

Certain payments to vendors reflect costs or deposits applicable to future accounting periods, are recorded as prepaid items, and are included in other assets in the statement of financial position.

PEDIATRIC CANCER RESEARCH FOUNDATION

NOTES TO THE FINANCIAL STATEMENTS

JUNE 30, 2025

NOTE 1 – Summary of Significant Accounting Policies (Continued)

Property and Equipment

Property and equipment are stated at cost if purchased and fair value if donated and depreciated using the straight-line method over the estimated useful lives (three to five years) of the assets. Leasehold improvements are amortized over the lesser of their useful lives or the lease term. Expenditures for repairs and maintenance are charged to supporting services when incurred; renewals and betterments are capitalized. Upon sale or disposal of property and equipment, the cost and accumulated depreciation are removed from the respective accounts, and any gain or loss is included in the statement of activities and changes in net assets. The Foundation's property and equipment were fully depreciated as of June 30, 2025.

Investment, at Cost

The Foundation classifies its investment in the right to certain shares of capital stock of a privately held company at cost. (See Note 4.)

Impairment of Long-Lived Assets

The Foundation's long-lived assets include property and equipment. In accordance with U.S. GAAP, long-lived assets are reviewed for impairment whenever events or changes in circumstances indicate that the carrying amount may not be recoverable. If the expected future cash flows from the use of the asset and its eventual disposition are less than the carrying amount of the asset, an impairment loss is recognized and measured using the fair value of the related asset. As of June 30, 2025, management did not identify any material impairment of the Foundation's long-lived assets.

Grants Payable

Grants payable consist of amounts awarded but not paid as of June 30, 2025.

Due to grant agreements requiring certain concessions, budgets, and forecasts from the grantees, grants are considered to have been awarded at the time the Foundation and the grantee executed the grant agreement for the first year of the grant period. Subsequent years of multi-year grants are considered to have been awarded upon receipt of certain reporting requirements from grantee organizations, as provided in the grant agreements.

PEDIATRIC CANCER RESEARCH FOUNDATION

NOTES TO THE FINANCIAL STATEMENTS

JUNE 30, 2025

NOTE 1 – Summary of Significant Accounting Policies (Continued)

Deferred Revenue

Deferred revenue represents funds received in advance of special events to be held in the subsequent year.

Revenue Recognition

Contributions are recognized as general public support revenue when the Foundation receives an unconditional promise to give from the donor.

All contributions are considered to be without donor restriction unless restricted by the donor. Amounts pledged that are to be received in future periods, or are received that are designated for future periods, or are restricted by the donor for specific purposes are reported as additions to net assets with donor restrictions. When a restriction has been satisfied, the related net assets with donor restrictions are reclassified to net assets without donor restrictions and reported in the statement of activities and changes in net assets as net assets released from restrictions.

Revenue from special events are recognized when the activities are held.

In-Kind Contributions

In-kind contributions are recorded at their estimated fair values on the date received and have no donor-imposed restrictions. For the year ended June 30, 2025, in-kind contributions related to special events of \$132,796 were recorded as contribution revenue and are included within special event revenue. The related donated goods were recognized as direct special event costs in the period the events occurred. In-kind contributions related to special events consist primarily of event promotional items, participant gift bag items, and auction items. These contributions were utilized in four of the Foundation's events during the year ended June 30, 2025.

Remaining in-kind contributions totaling \$17,374 represent general donated goods provided to support the Foundation's ongoing operations.

The Foundation receives a substantial number of services donated by individuals interested in the Foundation's objectives. Services provided generally involve the contribution of time to organize and administer fundraising campaigns and to provide necessary services. The value of such volunteer services has not been reflected in the accompanying financial statements since it does not meet the criteria for revenue recognition.

PEDIATRIC CANCER RESEARCH FOUNDATION

NOTES TO THE FINANCIAL STATEMENTS

JUNE 30, 2025

NOTE 1 – Summary of Significant Accounting Policies (Continued)

Allocation of Functional Expenses

The costs of providing the Foundation’s various programs and other activities have been summarized on a functional basis in the statement of activities and changes in net assets and the statement of functional expenses. Accordingly, certain costs have been allocated among the programs and supporting services benefited. Significant expenses that are allocated include the following:

<u>Expense</u>	<u>Method of Allocation</u>
Salaries and related expenses	Time and effort
Professional services	Time and effort
Rent and utilities	Usage by square footage

Income Taxes

The Foundation qualifies as a tax-exempt foundation under Section 501(c)(3) of the Internal Revenue Code and under the corresponding California tax codes. The Foundation is also registered in the states of New York, New Jersey, and Illinois.

Financial Accounting Standards Board (FASB) Accounting Standards Codification (ASC) Topic 740, *Income Taxes*, requires management to evaluate the tax positions taken by the Foundation and to recognize a tax liability if the Foundation has taken an uncertain position that more likely than not would not be sustained upon examination by the Internal Revenue Service. Management has analyzed the tax positions taken by the Foundation and has concluded that, as of June 30, 2025, there are no uncertain positions taken, or expected to be taken, that would require recognition of a liability or disclosure in the financial statements. The Foundation is subject to routine audits by taxing jurisdictions. The statute of limitations for federal and state purposes is generally three and four years, respectively.

PEDIATRIC CANCER RESEARCH FOUNDATION

NOTES TO THE FINANCIAL STATEMENTS

JUNE 30, 2025

NOTE 1 – Summary of Significant Accounting Policies (Continued)

Leasing Arrangements

The Foundation determines if an arrangement contains a lease at inception based on whether the Foundation has the right to control the asset during the contract period and other facts and circumstances.

The Foundation's policy for determining its lease discount rate used for measuring lease liabilities is to use the rate implicit in the lease whenever that rate is readily determinable. If the rate implicit in the lease is not readily determinable, then the Foundation has elected to use the risk-free discount rate, as permitted by U.S. GAAP, determined using a period comparable with that of the lease term.

The Foundation has elected a policy to account for short-term leases, defined as any lease with a term less than 12 months, by recognizing all components of the lease payment in the statement of activities and changes in net assets in the period in which the obligation for the payments is incurred.

Concentrations of Credit Risk

Under the Dodd-Frank Wall Street Reform and Consumer Protection Act, deposits of up to \$250,000 at Federal Deposit Insurance Corporation (FDIC)-insured institutions are covered by FDIC insurance. At times, deposits may be in excess of the FDIC insurance limit; however, management does not believe the Foundation is exposed to any significant related credit risk.

Reclassifications

Certain reclassifications have been made to prior period financial statement presentation to correspond to the current period's format.

Subsequent Events

Management has evaluated the impact of any subsequent events from the statement of financial position date through January 29, 2026, the date on which the accompanying financial statements were available to be issued and determined there were no additional items to disclose.

PEDIATRIC CANCER RESEARCH FOUNDATION

NOTES TO THE FINANCIAL STATEMENTS

JUNE 30, 2025

NOTE 2 – Liquidity and Availability of Resources

Financial assets available for general expenditure, that is, without donor or other restrictions limiting their use, within one year of the statement of financial position date, comprise the following:

Financial assets at year-end:	
Cash and cash equivalents	\$ 1,407,608
Investments	356,929
Contributions receivable	49,774
Pledges receivable due in one year	440,000
Net assets with donor restrictions	<u>(1,185,687)</u>
	 \$ <u>1,068,624</u>

The Foundation maintains a policy of structuring its financial assets to be available as its general expenditures, liabilities, and other obligations come due.

NOTE 3 – Investments

The Foundation follows the guidance required for fair value measurements of financial and nonfinancial assets and liabilities that are recognized or disclosed at fair value in the financial statements on a recurring or nonrecurring basis. The fair value of a financial instrument is the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. Fair value is best determined based upon quoted market prices. However, in certain instances, there are no quoted market prices for the Foundation’s various financial instruments. In cases where quoted market prices are not available, fair values are based on estimates using present value or other valuation techniques.

The Foundation groups its assets measured at fair value into three levels, based on the markets in which the assets are traded and the reliability of the assumptions used to determine fair value. The three levels of the fair value hierarchy are as follows:

- Level 1 inputs are quoted prices (unadjusted) in active markets for identical assets or liabilities that the Foundation has the ability to access at the measurement date.
- Level 2 inputs are inputs other than quoted prices included within level 1 that are observable for the assets or liabilities, either directly or indirectly.
- Level 3 inputs are unobservable inputs for the assets or liabilities.

PEDIATRIC CANCER RESEARCH FOUNDATION

NOTES TO THE FINANCIAL STATEMENTS

JUNE 30, 2025

NOTE 3 – Investments (Continued)

At June 30, 2025, the Foundation’s investments are set forth by level within the fair value hierarchy as follows:

June 30, 2025	Fair Value			Total
	Level 1	Level 2	Level 3	
Fixed incomes	\$ -	\$ 250,676	\$ -	\$ 250,676
Mutual funds	106,253	-	-	106,253
	\$ 106,253	\$ 250,676	\$ -	\$ 356,929

Total investment return, net for the year ended June 30, 2025 is as follows:

Dividends	\$ 64,553
Realized and unrealized gains	27,091
Total investment return, net	\$ 91,644

NOTE 4 – Investment, at Cost

During the year ended December 31, 2021, the Foundation invested \$250,000 in a Simple Agreement for Future Equity (SAFE) with Oncoheroes Biosciences Inc. (Oncoheroes). The SAFE investment gives the Foundation the right to certain shares of Oncoheroes’ capital stock, which is carried at cost. The right to shares is available to the Foundation upon a change in control or initial public offering by Oncoheroes, both defined as a liquidity event in the agreement. If there is a liquidity event, and the right to receive Oncoheroes’ shares is not exercised by the Foundation, the Foundation will receive a cash payment of 200% of the investment amount. This investment has not been evaluated for impairment because it is not practicable to estimate the fair value due to insufficient information being available. Management has not identified any events or changes in circumstances that might have a significant adverse effect on the fair value of the investment. The fair value of this investment may differ from the amount recorded.

PEDIATRIC CANCER RESEARCH FOUNDATION

NOTES TO THE FINANCIAL STATEMENTS

JUNE 30, 2025

NOTE 5 – Pledges Receivable

At June 30, 2025, pledges receivable, net, is due in amounts as follows:

Amounts due in:	
Less than one year	\$ 440,000
One to five years	<u>807,500</u>
	1,247,500
Less discount to present value	<u>72,363</u>
Pledges receivable, net	<u>\$ 1,175,137</u>

NOTE 6 – Leasing Arrangements

The Foundation lease office spaces in Irvine under operating leases with three-to-five year initial terms. One of the leases includes a renewal option which can extend the lease term for an additional five years. The exercise of the renewal option is at the sole discretion of the Foundation, and only lease options that the Foundation believes are reasonably certain to exercise are included in the measurement of the lease assets and liabilities.

Variable payments that are not determinable at the lease commencement are not included in the measurement of the lease assets and liabilities. The lease agreements do not include any material residual value guarantees or restrictive covenants.

The following summarizes the line items in the statement of financial position which include amounts for operating leases as of June 30, 2025:

Operating lease right-of-use assets	<u>\$ 279,896</u>
Operating lease liabilities	<u>\$ 323,952</u>

The components of operating lease expenses that are included in “rent and utilities” in the statement of functional expenses were as follows for the year ended June 30, 2025:

Operating lease costs	<u>\$ 96,579</u>
-----------------------	------------------

PEDIATRIC CANCER RESEARCH FOUNDATION

NOTES TO THE FINANCIAL STATEMENTS

JUNE 30, 2025

NOTE 6 – Leasing Arrangements (Continued)

The following summarizes the supplemental cash flow information related to leases for the year ended June 30, 2025:

Cash paid for amounts included in the measurement of lease liabilities:

Operating cash flows from operating leases	\$	74,224
--	----	--------

Noncash investing and financing activity:

Right-of-use assets obtained in exchange for operating lease liabilities in adopting ASC 842	\$	115,099
--	----	---------

The weighted-average remaining lease term and discount rate for the operating leases as of June 30, 2025 were as follows:

Weighted-average remaining lease term	2.5 years
Weighted-average discount rate	3.26%

The maturities of operating lease liabilities as of June 30, 2025 are as follows:

Year Ending June 30,	Operating Lease
2026	\$ 130,915
2027	136,039
2028	70,117
Total minimum lease payments	337,071
Less amount representing interest	(13,119)
Present value of minimum lease payments	\$ 323,952

PEDIATRIC CANCER RESEARCH FOUNDATION

NOTES TO THE FINANCIAL STATEMENTS

JUNE 30, 2025

NOTE 7 – Contingencies

Legal

In the normal course of business, the Foundation may become a party to litigation. Management believes there are no asserted or unasserted claims or contingencies that would have a significant impact on the financial statements of the Foundation as of June 30, 2025.

NOTE 8 – Employee Benefit Plan

The Foundation adopted a SIMPLE IRA retirement program. The Foundation expects to make matching contributions of 1% to 3%, with a mandatory matching contribution of 3% to be made in at least one year of every three-year period. The Foundation made \$21,705 in matching contributions under the SIMPLE IRA retirement program during the year ended June 30, 2025.

PEDIATRIC CANCER RESEARCH FOUNDATION

NOTES TO THE FINANCIAL STATEMENTS

JUNE 30, 2025

NOTE 9 – Net Assets with Donor Restrictions

The activity throughout the year for net assets with and without donor restrictions is as follows:

<u>Program Name</u>	<u>Balance at June 30, 2024</u>	<u>Contributions</u>	<u>Expenditures/ Releases</u>	<u>Balance at June 30, 2025</u>
Net assets without donor restrictions	\$ 1,190,249	\$ 3,083,602	\$ (3,747,617)	\$ 526,234
Net assets with donor restrictions				
Survivor scholarship	\$ -	\$ 378,152	\$ (146,450)	231,702
Asher Johnston Fund	-	82,000	-	82,000
Time restricted - special events	-	261,930	-	261,930
Time restricted - long-term pledges receivable	-	610,055	-	610,055
	<u>-</u>	<u>1,332,137</u>	<u>(146,450)</u>	<u>1,185,687</u>
Total	<u>\$ 1,190,249</u>	<u>\$ 3,805,684</u>	<u>\$ (3,894,067)</u>	<u>\$ 1,711,921</u>